Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T therapy could ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Its investment in CAR-T drugs is part of that ambitious push, and 2017 is set to be a decisive year for Novartis and main rival, Kite Pharma, who lead this hugely promising but risky field.

Kash is known to Israelis mainly for his books "Success Tactics You Won't Learn in Business School" "Freedom from Disease" ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

Macquarie Group Ltd (ASX: MQG) has appointmented David Chang as the Head of Wealth Distribution in Asia, effective March 2, ...

The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare providers, and the public about the revolutionary progress of CAR T-cell ...

After hours: March 6 at 6:26:52 PM EST Loading Chart for KRG ...

What does Nifty Pharma represent? Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends ...